Non‐fatal myocardial infarction/stroke · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people at increased risk for developing type 2 diabetes
It is very uncertain whether summary of findings: pioglitazone monotherapy changes all‐cause mortality (N) compared with no intervention (very low certainty).
1 finding from 1 review
Incidence of T2DM (N) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy probably leads to lower incidence of T2DM (N) Diagnostic criteria: 9 studies applied the WHO… compared with no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy showed no clear difference in serious adverse events (N) compared with no intervention (low certainty).
1 finding from 1 review
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐fatal myocardial infarction/stroke · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes cardiovascular mortality compared with no intervention (very low certainty).
1 finding from 1 review
(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes (a)Non‐fatal myocardial infarction (b)Non‐fatal stroke (c)Congestive… compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Development of type 2 diabetes · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes incidence of T2DM compared with no intervention (very low certainty).
1 finding from 1 review
Cancer occurrence · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D showed no clear difference in cancer occurrence compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Cancer occurrence in trials using vitamin D₃ (cholecalciferol) · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D showed no clear difference in cancer occurrence in trials using vitamin D₃ (cholecalciferol) compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
All‐cause mortality · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D may leads to lower all‐cause mortality compared with placebo or no intervention (low certainty).
1 finding from 1 review